Costs for Orally Administered Cancer Drugs Up Since 2000

Share this content:
Costs for Orally Administered Cancer Drugs Up Since 2000
Costs for Orally Administered Cancer Drugs Up Since 2000

FRIDAY, April 29, 2016 (HealthDay News) -- Prices of orally administered cancer medications in the United States have risen sharply since 2000, according to a study published online April 28 in JAMA Oncology.

The average cost of a new orally administered cancer medication introduced in 2000 was about $1,869 a month, compared with $11,325 a month for one approved in 2014, about six times higher, United Press International reported.

Gleevec had one of the largest price increases during that time, rising about 7.5 percent a year and increasing from $3,346 to $8,479 a month, according to the University of North Carolina researchers.

The researchers said the escalating prices have occurred along with health insurance changes making patients bear more of the cost and potentially making treatment unaffordable for some, UPI reported.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

CDC: Too Many Health Care Workers Not Getting Flu Vaccine

CDC: Too Many Health Care Workers Not Getting ...

Vaccination protects both workers and patients

Early Mobilization Improves Outcomes, LOS in Surgical ICUs

Early Mobilization Improves Outcomes, LOS in Surgical ICUs

Patients discharged sooner, become more functional when they leave the hospital

is free, fast, and customized just for you!

Already a member?

Sign In Now »